Clinical trials: PAOD (Peripheral Arterial Obstructive Disease)
Peripheral Arterial Occlusive Disease, Critical Limb Ischemia
Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)
The goal of this Phase 0 clinical trial is to evaluate safety and biodistribution of [89Zr]Zr-DFO-APAC in patients with peripheral arterial occlusive disease / critical limb ischemia (PAOD/CLI) and healthy volunteers.
- Trial name
- CHASE (NCT06204237)
- Testing
- [89Zr]Zr-DFO-APAC, PET/CT scan
- Where
- Netherlands
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Aplagon Oy
PAOD - Peripheral Arterial Occlusive Disease
Peripheral Artery Occlusive Disease (PAOD) in Women Hospitalized for Type 1 Myocardial Infarction in Intensive Cardiology Care
The cardiovascular risk of women has been the subject of particular interest in recent years, in the world, in particular under the impetus of Cardiology companies, with more and more work focusing on the specificities of these…
- Trial name
- AOMI (NCT05149456)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Peripheral Arterial Occlusive Disease
Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of Peripheral Arterial Occlusive Disease-related clinically relevant ulcers) and safety (by monitoring adverse events) of one…
- Trial name
- NCT03339973
- Testing
- allo-APZ2-PAOD
- Where
- 18 sites in Austria, Czechia and 3 more
- Volunteers
- 24 people
- Sponsor
- RHEACELL GmbH & Co. KG
Critical Limb Ischemia
Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)
Critical Limb Ischemia prevents the legs and feet from receiving oxygen and nutrients needed for proper function. This severe lack of blood flow can lead to painful legs while walking or at rest and can result in foot sores…
- Trial name
- NCT01245335
- Testing
- BMAC injection
- Where
- 34 sites in United States
- Volunteers
- 97 people
- Sponsor
- Harvest Technologies
Peripheral Vascular Disease, Diabetic Foot
Autologous Bone Marrow Stem Cell Transplantation for Critical, Limb-threatening Ischemia
Critical limb ischemia is a condition where the blood circulation in the limbs, in most cases the legs, is decreased so that pain and non healing wounds ensue. Mostly, this is a sequel of arteriosclerosis and/or diabetes.
- Conditions
- Peripheral Vascular Disease, Diabetic Foot, Peripheral Arterial Occlusive Disease, Leg Ulcer
- Trial name
- BONMOT (NCT00434616)
- Testing
- Autologous bone marrow cell concentrate transplantation, saline injection
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Franziskus-Krankenhaus
Peripheral Arterial Occlusive Disease
Isovue in Peripheral Digital Subtraction Angiography (DSA)
No significant differences is expected in observed motion artifacts, heat or pain reported during peripheral DSA performed for diagnostic and/or endovascular therapeutic purposes.
- Trial name
- NCT01075217
- Testing
- iopamidol, iodixanol
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Bracco Diagnostics, Inc
Intermittent Claudication
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
Peripheral arterial disease (PAD) is almost invariably associated with a generalized atherosclerotic involvement of the arterial tree and endothelial dysfunction.
- Trial name
- NCT01256775
- Testing
- NCX-4016
- Where
- Italy
- Volunteers
- 442 people
- Sponsor
- NicOx Research Institute S.r.l.
Peripheral Arterial Occlusive Disease
Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation
The primary objective is to evaluate the transgene expression (synthesis of FGF-1 mRNA) in injected tissue, at injection site, after Intra Muscular (IM) administration of increasing single doses of NV1FGF.
- Trial name
- NCT01157143
- Testing
- XRP0038 (NV1FGF)
- Where
- 2 sites in United States, Switzerland
- Volunteers
- 6 people
- Sponsor
- Sanofi
Peripheral Vascular Disease
Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.
To determine the safety and efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in subjects with atherosclerotic de novo or restenotic lesions in the native common iliac artery and/or native external iliac artery.
- Trial name
- MOBILITY AP (NCT00844532)
- Testing
- Absolute Pro™ Peripheral Self-Expanding Stent System
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- Abbott Medical Devices
Peripheral Vascular Disease
Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery
To determine the safety and efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in subjects with atherosclerotic de novo or restenotic lesions in the native common iliac artery and/or native external iliac…
- Trial name
- MOBILITY OE (NCT01396525)
- Testing
- Omnilink Elite™ Peripheral Balloon-Expandable Stent System
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Abbott Medical Devices
Severe Peripheral Artery Occlusive Disease
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.
Peripheral Arterial Occlusive Disease (PAOD) is a condition caused by ischemia in the legs due to atherosclerotic disease affecting the larger arteries of the legs.
- Trial name
- TALISMAN202 (NCT00798005)
- Testing
- XRP0038 (NV1FGF)
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Sanofi
Peripheral Arterial Occlusive Disease (PAOD)
Evaluation of FUSION™ Vascular Graft for Above Knee Targets
The purpose of the post-market study was to evaluate the safety and performance of the FUSION Vascular Graft.
- Trial name
- PERFECTION (NCT01601496)
- Testing
- FUSION Vascular Graft
- Where
- 10 sites in Austria, Germany
- Volunteers
- 117 people
- Sponsor
- Maquet Cardiovascular
Peripheral Arterial Disease, Cardiovascular Diseases
Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs
The primary objective of this trial is to investigate whether intramuscular administration of allogeneic mesenchymal stromal cells (MSC) is safe and potentially effective, assessed as a composite outcome of mortality, limb…
- Conditions
- Peripheral Arterial Disease, Cardiovascular Diseases, Vascular Diseases
- Trial name
- SAIL (NCT03042572)
- Testing
- Allogeneic Mesenchymal Stromal Cell
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Martin Teraa, MD, PhD
PAOD (Peripheral Arterial Obstructive Disease)
Impact and Safety of Blood Flow Restriction in Patients With Peripheral Arterial Occlusive Disease
In peripheral arterial occlusive disease (PAOD), there is a partial (stenosis) or complete occlusion of peripheral arteries, which leads to reduced arterial blood flow.
- Trial name
- NCT07043114
- Testing
- BFR-Walking
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital, Bonn